Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates

Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates

Show other versions (1)

Malaria is a major health problem as nearly half of the human population is exposed to this parasite causing around 600 million clinical cases annually. Prime-boost regimes using simian adenoviral vectors and MVA expressing the clinically relevant Plasmodium falciparum ME.TRAP antigen have shown out...

Full description

Bibliographic Details
Main Authors:	Capone, S, Reyes-Sandoval, A, Naddeo, M, Siani, L, Ammendola, V, Rollier, C, Nicosia, A, Colloca, S, Cortese, R, Folgori, A, Hill, A
Format:	Journal article
Language:	English
Published:	2010

Similar Items

Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates.
by: Capone, S, et al.
Published: (2010)

NEUTRALIZING ANTIBODY TITERS TO SIMIAN ADENOVIRAL VECTORS FOLLOWING ADCH63 ME-TRAP IMMUNIZATION IN HUMANS
by: Goodman, A, et al.
Published: (2009)

EVALUATION OF SIMIAN ADENOVIRAL VECTOR ADCH63 EXPRESSING MSP-1 AS A CANDIDATE BLOOD-STAGE MALARIA VACCINE
by: Goodman, A, et al.
Published: (2009)

HETEROLOGOUS PRIME-BOOST VACCINATION WITH ADCH63 AND MVA EXPRESSING MSP1 CAN INDUCE PROTECTIVE EFFICACY AGAINST SPOROZOITE CHALLENGE IN VOLUNTEERS
by: Sheehy, S, et al.
Published: (2010)

A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory
by: Swadling, L, et al.
Published: (2014)

PHASE I TRIAL OF A HIGHLY IMMUNOGENIC T CELL VACCINE FOR HEPATITIS C VIRUS BASED ON NOVEL ADENOVIRAL VECTORS FROM RARE SEROTYPES
by: Folgori, A, et al.
Published: (2009)

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.
by: O'Hara, G, et al.
Published: (2012)

Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation
by: Ewer, K, et al.
Published: (2013)

A THERAPEUTIC VACCINE FOR HCV BASED ON NOVEL, RARE, ADENOVIRAL VECTORS
by: Kelly, C, et al.
Published: (2011)

Chimpanzee adenoviral vectors as vaccines – challenges to move the technology into the fast lane
by: Alessandra Vitelli, et al.
Published: (2017-12-01)

PHASE I TRIAL OF A HIGHLY IMMUNOGENIC AND DURABLE T-CELL VACCINE FOR HEPATITIS C VIRUS BASED ON NOVEL, RARE, ADENOVIRAL VECTORS
by: Barnes, E, et al.
Published: (2011)

PHASE I TRIAL OF A HIGHLY IMMUNOGENIC T-CELL VACCINE FOR HEPATITIS C VIRUS BASED ON NOVEL ADENOVIRAL VECTORS FROM RARE SEROTYPES
by: Barnes, E, et al.
Published: (2009)

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
by: Ogwang, C, et al.
Published: (2013)

Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species.
by: Colloca, S, et al.
Published: (2012)

IN VIVO ANTIGENIC TARGETS OF T CELLS INDUCED BY ADENOVIRAL VECTORED VACCINES IN PATIENTS WITH CHRONIC HCV INFECTION
by: Kelly, C, et al.
Published: (2012)

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
by: Caroline Ogwang, et al.
Published: (2013-01-01)

Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.
by: Sheehy, S, et al.
Published: (2011)

Phase Ia clinical evaluation of the plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors
by: Sheehy, S, et al.
Published: (2011)

Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.
by: Green, C, et al.
Published: (2015)

Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses.
by: Reyes-Sandoval, A, et al.
Published: (2010)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and ChAdV-63 in a phase I/IIa clinical trial
by: Hanke, T, et al.
Published: (2012)

Erratum: Prime-boost immunization with adenoviral and modified vaccinia virus ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses
by: Reyes-Sandoval, A, et al.
Published: (2011)

Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8(+) T-Cell Responses, (vol 78, pg 152, 2010)
by: Reyes-Sandoval, A, et al.
Published: (2011)

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
by: Sheehy, S, et al.
Published: (2012)

In vivo editing of the pan-endothelium by immunity evading simian adenoviral vector
by: Reka Lorincz, et al.
Published: (2023-02-01)

Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults.
by: Green, C, et al.
Published: (2015)

A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.
by: Fitzgerald, J, et al.
Published: (2003)

Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes.
by: Reyes-Sandoval, A, et al.
Published: (2004)

Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei.
by: Reyes-Sandoval, A, et al.
Published: (2008)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial
by: Borthwick, N, et al.
Published: (2012)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial
by: Borthwick NJ, et al.
Published: (2012-09-01)

Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.
by: Kimani, D, et al.
Published: (2014)

Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals.
by: Hodgson, S, et al.
Published: (2014)

ChAd63-MVA-vectored blood-stage Malaria vaccines targeting MSP1 and AMA1: Assessment of efficacy against mosquito bite challenge in humans
by: Sheehy, S, et al.
Published: (2012)

Distinct patterns of whole blood transcriptional responses are induced in mice following immunisation with adenoviral and poxviral vector vaccines encoding the same antigen
by: Sheerin, D, et al.
Published: (2021)

Correction: Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei
by: Reyes-Sandoval, A, et al.
Published: (2011)

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African children and infants
by: Bliss, C, et al.
Published: (2016)

Distinct patterns of whole blood transcriptional responses are induced in mice following immunisation with adenoviral and poxviral vector vaccines encoding the same antigen
by: Dylan Sheerin, et al.
Published: (2021-10-01)

Primates (Animal Group That Contains Prosimians and Simians) /
by: Pham, Jospeh, author 648809
Published: (2012)

A Phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS
by: De Barra, E, et al.
Published: (2014)